Clinical Trials Sponsored by ThromboGenics

Total 31 results

ThromboGenics

Completed

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

Symptomatic Vitreomacular Adhesion

United States, Belgium
ThromboGenics

Completed

A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA (OZONE)

Symptomatic Vitreomacular Adhesion (VMA)

United States
ThromboGenics

Completed

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.

Vitreomacular Adhesion

United States, Spain, United Kingdom, Germany, Belgium, Czech Republic, Poland
ThromboGenics

Completed

A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)

Vitreomacular Traction

Belgium, Germany
ThromboGenics

Completed

The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) (MIVI-10)

Vitrectomy

Belgium
ThromboGenics

Terminated

Intra-arterial Microplasmin Administration in Patients With Acute Intracranial Vertebrobasilar Artery Occlusion (MITI-IA)

Stroke

Netherlands, Germany
ThromboGenics

Completed

Ocriplasmin Research to Better Inform Treatment (ORBIT) (ORBIT)

Symptomatic Vitreomacular Adhesion

United States
ThromboGenics

Completed

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)

Vitrectomy

United States
ThromboGenics

Completed

Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

Vitreomacular Adhesion

United States
ThromboGenics

Completed

Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke

Stroke, Acute

Germany, Belgium, Austria
ThromboGenics

Terminated

Intra-arterial Microplasmin Administration in Patients With Acute Peripheral Arterial Occlusion

Arterial Occlusive Diseases

Belgium
ThromboGenics

Completed

Safety and Efficacy Study of Microplasmin in for Non-Surgical Treatment of Focal Vitreomacular Adhesion (MIVI-8)

Focal Vitreomacular Adhesion

Belgium
ThromboGenics

Completed

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Diabetic Retinopathy | Macular Edema

Czechia, Slovakia, Hungary
ThromboGenics

Completed

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS)

Vitreomacular Adhesion Including Macular Hole

United States
ThromboGenics

Completed

Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion (MIVI-5)

Exudative Age-Related Macular Degeneration | Focal Vitreomacular Adhesion

United States, United Kingdom, Germany, France, Belgium, Italy
ThromboGenics

Completed

A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) (MIVI-II)

Diabetic Macular Edema

Spain, Belgium, United Kingdom, Italy, Netherlands, Germany
ThromboGenics

Completed

Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy (MIC)

Vitrectomy

United States
ThromboGenics

Completed

Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy

Eye Diseases | Vitreomacular Traction Maculopathy

Belgium, Netherlands
ThromboGenics

Completed

A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

Retinal Telangiectasis | Idiopathic Juxtafoveal Retinal Telangiectasia

France, Switzerland
ThromboGenics

Terminated

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR (CIRCLE)

Disease Progression | Diabetic Retinopathy | Posterior Vitreous Detachment

United States, Czechia, United Kingdom, France, Germany, Hungary, Spain, Israel, Italy
ThromboGenics

Completed

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

United States
ThromboGenics

Completed

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Diabetes Mellitus | Diabetic Retinopathy | Diabetic Macular Edema

United States
ThromboGenics
Bacchus Vascular

Terminated

Microplasmin Administered Via the Trellis-8 Infusion System for Treatment of Acute Iliofemoral DVT (MAX-DVT)

Deep Vein Thrombosis

Ireland
ThromboGenics
BioInvent International AB

Completed

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Prophylaxis of Venous Thromboembolic Events

Austria, Netherlands, Belgium, Bulgaria, Hungary, Latvia, Poland, Russian Federation, Ukraine
ThromboGenics
BioInvent International AB

Completed

Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin

Healthy

Denmark
ThromboGenics
BioInvent International AB

Completed

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402

Healthy

Denmark
ThromboGenics
BioInvent International AB

Completed

A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers

Healthy

Denmark
ThromboGenics
Covance; BioInvent International AB

Completed

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

Total Knee Replacement Surgery

Israel, Romania, Bulgaria, Latvia, Poland, Russian Federation, Ukraine
Wagner Macula & Retina Center
ThromboGenics

Terminated

Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) (TOTEM)

Vitreomacular Traction | Subretinal Edema

United States
University of California, Los Angeles
ThromboGenics

Unknown

Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration (AMD)

Macular Degeneration

United States
Nova Southeastern University
ThromboGenics; Optovue; Carl Zeiss Meditec, Inc.

Completed

Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older (VAST)

Vitreomacular Adhesion

United States

3

Subscribe